How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moderately-to-severely-active-ulcerative-colitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moderately to severely active ulcerative colitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moderately to severely active ulcerative colitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moderately to severely active ulcerative colitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Omvoh	MIRIKIZUMAB	Eli Lilly Nederland B.V.	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha		2023-01-01
OMVOH	MIRIKIZUMAB-MRKZ	ELI LILLY AND CO	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

ELI LILLY AND CO · 1 drug in Moderately to severely active ulcerative colitis
Eli Lilly Nederland B.V. · 1 drug in Moderately to severely active ulcerative colitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moderately to severely active ulcerative colitis:

Cite this brief

Drug Landscape (2026). Moderately to severely active ulcerative colitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moderately-to-severely-active-ulcerative-colitis. Accessed 2026-06-10.

Moderately to severely active ulcerative colitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing